Novel ciprofloxacin-resistant, nalidixic acid-susceptible mutant of Staphylococcus aureus.
A ciprofloxacin-resistant, nalidixic acid-susceptible mutant of Staphylococcus aureus (F145) contained no mutations within gyrA, gyrB, grlA, and grlB or within norA or its promoter region. MICs and accumulation studies suggest the role of a novel multidrug efflux pump.
Piddock
Laura J V
LJ
Antimicrobial Agents Research Group, Division of Immunity & Infection, University of Birmingham, Birmingham B15 2TT, United Kingdom. L.j.v.piddock@bham.ac.uk
Jin
Yu Fang
YF
Webber
Mark A
MA
Everett
Martin J
MJ
D000890:Anti-Infective Agents / Q000494:pharmacology*; D002258:Carbonyl Cyanide m-Chlorophenyl Hydrazone / Q000494:pharmacology; D002939:Ciprofloxacin / Q000494:pharmacology*; D008826:Microbial Sensitivity Tests; D009154:Mutation; D009268:Nalidixic Acid / Q000494:pharmacology*; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000235:genetics
D000890:Anti-Infective Agents; D009268:Nalidixic Acid; D002258:Carbonyl Cyanide m-Chlorophenyl Hydrazone; D002939:Ciprofloxacin